Our team will be unavailable from December 25, 2023, to January 1, 2024.
We will resume operations on January 2, 2024. Wishing you a joyful holiday season!

There’s a national shortage of a children’s drug. This Columbia manufacturer is stepping up

Ritedose

A Columbia pharmaceutical manufacturer is ramping up production of a critically needed drug in response to a national shortage.

Ritedose has launched emergency production of a rare albuterol dosage needed for pediatric asthma patients, in response to demand from hospitals around the country that were having trouble getting children the medicine they need.

The drug has been in short supply since last year as the handful of manufacturers who produce albuterol have faced production issues.

One albuterol producer, Akorn Operating Company, declared bankruptcy in 2020 and ended all production when it went out of business in February, CNN reports. That same month, the only other albuterol producer in the country — Cayce-based Nephron Pharmaceuticals — put many of its employees on furlough. That left many health care providers scrambling to find new sources of the drug.

“We actually had patients, not hospitals, reaching out to us directly to ask, ‘Can you make this? We need this drug. My child needs this drug,’” said Ritedose president Jody Chastain.

Ritedose had made albuterol products for decades, but not the special nebulizer commonly used as an inhaled remedy for breathing issues in doctor’s offices and children’s hospitals. It’s a very specific, niche need — Chastain estimates it represents about 2% of the market for albuterol products — which is why so few companies specialize in producing it.

“From a straight financial perspective, you wouldn’t make it. There’s not enough of a market for it,” Chastain said. “But we want to do the right thing for the patients.”

Ritedose has started continuous production under an emergency need measure, shipping the needed drug across the country. The company will continue making albuterol throughout the shortage, Chastain said, but Ritedose is asking the Food and Drug Administration for approval to continue making the drug long-term.

Other drug makers have also stepped up to produce albuterol during the shortage, but Ritedose will be the only one producing the drug in a blow fill seal where other manufacturers are pre-filling the drug in a syringe. The automated seal allows a doctor to release the sterile liquid into an inhaler to be turned into a breathable mist.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.